Treatment options for primary sclerosing cholangitis.

Area of Science:

• Hepatology
• Gastroenterology
• Immunology

Background:

• Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease.
• It involves inflammation and fibrosis of bile ducts, leading to strictures and cirrhosis.
• PSC is linked to inflammatory bowel disease and increased cancer risk.

Purpose of the Study:

• To review the current understanding of PSC.
• To highlight the lack of effective medical treatments.
• To discuss current and future therapeutic strategies.

Main Methods:

• Literature review of primary sclerosing cholangitis.
• Analysis of current treatment efficacy and adverse events.
• Evaluation of potential therapeutic targets and ongoing research.

Main Results:

• No current medical therapy effectively halts PSC progression.
• Ursodeoxycholic acid has shown ineffectiveness and increased adverse events at high doses.
• Endoscopic or radiological dilatation offers symptomatic relief for dominant strictures.

Conclusions:

• Liver transplantation is the sole life-prolonging treatment for end-stage PSC.
• Novel therapeutic approaches including antibiotics, antifibrotic agents, and bile acid derivatives are under investigation.
• Further research is crucial for developing effective treatments for PSC.